Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 15, 2004

View Archived Issues

Antares Pharma announces agreement with ProSkelia

BattellePharma now Ventaira Pharmaceuticals

Celltech Group achieves milestone in osteoporosis collaboration with Amgen

Genome Therapeutics and Amgen conclude research agreement

Pierre Fabre presents protein prenyltransferase inhibitors for cancer and other disorders

Almirall Prodesfarma identifies new H1 antagonists with good selectivity profile

Novel orally bioavailable VLA-4 antagonists under study at Elan

BMS scientists claim Eg5 inhibitors and their use in cancer therapy

Chiron expands its phase II program for IL-2 in the treatment of lymphoma

Glycopeptide-cephalosporin conjugates prepared and tested at Theravance

Sanofi-Synthelabo presents beta3-AR agonists for GI disorders and other uses

Allergan claims novel alpha2-AR agonists with potential as analgesic agents

Thios licenses rPSGL-Ig from Wyeth

Medicure looks back at milestone developments

Archemix and Nuvelo enter development agreement for ARC-183

Kemin Pharma develops two new molecules for HCV

Eloxatin approved for first-line treatment of advanced colorectal cancer

BioStratum and Novo Nordisk to develop antibodies to laminin-5 for cancer

Approvable letter for Cipher's fenofibrate formulation

Phase III R-modafinil program progresses towards Q4 NDA filing

MPI-176716 produces tumor regression in animal models of ovarian cancer

Schering-Plough/Pharmacopeia collaborative compound enters clinical trials

New phase I trial for Traficet-EN

Phase II trial confirms icatibant utility in hereditary angioedema

Second pivotal trial of methylnaltrexone for opioid-induced constipation

Namenda available for moderate to severe Alzheimer's disease

Significant improvements reported for tacrolimus ointment in cutaneous lupus erythematosus

Eszopiclone improves sleep onset, maintenance and quality in patients with chronic insomnia

Low-dose DHEA supplements improve endocrine parameters in postmenopausal women

Identification of anthrax lethal factor inhibitors

Novel class of farnesyltransferase inhibitors synthesized by Abbott

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...